Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In for 10k, nice heads up! thanks ~Rig
No kidding! It looks like the .23 has other bidders as well
http://investorshub.advfn.com/boards/read_msg.asp?message_id=24205007&txt2find=pltt+
PR'ing this news will send it through the roof.
Yup, I'd steal more if I could too!
I think I was lucky enough to get the last of the .23's.
They upticked right after my buy, otherwise I would have bought more at .23 too.
Talk about a varied background: "...Ross brings over 20 years experience leading R&D, New Product Development and New Ventures for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi."
Now let's see what he can do for PLTT.
I would have no complaints with that.
As we've seen before, this thing moves on next to nothing....could be an interesting November.
Still sitting at .23 but I'm now thinking that isn't going to happen.
Updated Executive Team link: http://www.pilottherapeutics.com/4.html
Executive Leadership Team
Ross Consaul , CEO. As CEO of Pilot, Ross brings over 20 years experience leading R&D, New Product Development and New Ventures for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi. Skilled at matching technology possibilities with market needs he has created and launched new products and businesses with total annual sales of $2 billion across multiple categories, brands and channels. He has also been instrumental in identifying, acquiring and integrating new businesses with combined annual sales of $3 billion.
Ross was most recently Nutrition General Manager, Bayer BioScience, where he was responsible for identifying and creating new businesses in health and nutrition for the $38 billion Bayer Company. In this role, he identified and developed comprehensive business plans for new opportunities with combined annual revenue projections in excess of $1.5 billion.
Before joining Bayer, Ross was Head of Innovation in the Research Quality and Technology group at the $9 billion Kellogg Company, accountable for developing new product and business opportunities and leading technology discovery.
Keith Wakeman, President. As President of Pilot, Keith brings over 20 years food and nutrition industry experience leading marketing, innovation, and new ventures organizations across a broad range of categories and brands. Keith was head of Innovation for the $2 billion Kellogg’s Snacks Division and led New Ventures for both the $9 billion Kellogg Company and the $2 billion Keebler Company. He also led brand teams and held various trade marketing and sales roles at Nabisco, Leaf and Procter & Gamble. Keith has developed and launched new products generating nearly $1 billion revenue.
Prior to joining Pilot, Keith was President of Cherry Street Innovation LLC, an innovation company he founded to identify and develop new growth platforms through new ventures and brand innovation. Through his leadership, CSI identified opportunities and developed business plans for new ventures projected to generate nearly $2 billion annual revenue.
Keith serves on the Boards of several entrepreneurial companies including a start-up branded organic beef business and big Boing, a product innovation and brand launch company.
Ski Chilton, Chief Technology Officer. Dr. Chilton is widely recognized in academia and industry for his work on the role of fatty acid metabolism in human diseases. He has extensive experience in leading organizations in both of these areas. Dr. Chilton is currently a Full Professor in the Department of Physiology and Pharmacology and Director of the Wake Forest and Brigham and Women’s Center for Botanical Lipids at Wake Forest University Health Sciences. Dr. Chilton also founded the Program in Molecular Medicine at Wake Forest University Health Sciences and helped build it into one of the most successful Programs of its kind in the United States. During his time in academia, Dr. Chilton has served as Director of Molecular Medicine, Professor of Physiology and Pharmacology, Professor of Internal Medicine and Professor of Biochemistry at the Wake Forest University as well as Assistant Professor of Internal Medicine at the Johns Hopkins School of Medicine. He also served as Associate Director of the Asthma and Airways Diseases Center and Associate Director of Programs in Clinical Research at Wake Forest University Health Sciences. Dr. Chilton has served as Chairman and has organized several international meetings on dietary regulation of human disease and lipid metabolism.
Dr Chilton has authored or co-authored over 110 scientific articles and book chapters. He holds 32 issued and 17 pending patents. In 2005, Dr. Chilton wrote a book, Inflammation Nation, which was published by Simon and Schuster. In 2006, he wrote Win the War Within, which was published by Rodale.
Dr. Chilton obtained his Ph.D. in Biochemistry from Wake Forest University in 1984. He served as a Postdoctoral Fellow in Pharmacology at the University of Colorado until 1986. He has received numerous awards in his career including the Cowgill Scholar Award at Wake Forest, the Sigma Xi Research Award at Wake Forest, the 1999 Distinguished Academic and Achievement Award from Western Carolina University and The Distinguished Service and Teaching Award from the Italian Congress on Allergy and Immunology.
Scott Derks, Chief Operations Officer. Scott combines the practical skills of a veteran banker with the creative drive of an award winning writer who has authored 14 books. He spent 20 years managing cultural change, profitability and merger activity during the consolidation of the banking industry in the 1980s and 1990s. During his last three years in banking, he served as a Senior executive with Bank of America and Chief of Staff to the company's flagship North Carolina and South Carolina operation.
For the past two years he has orchestrated the renaissance of Pilot Therapeutics from dormancy to re-launch first as a consultant, then as president. During that time he has focused on establishing a commercial foundation for Pilot in partnership with Wake Forest Medical University.
Scott’s most recent book is Working Americans: Social Movements 1880-2006, his seventh book in the series. He also serves on the board of CIVISonLine, an internet company working with the BBC, New York Times and Yahoo to create the ‘global conversation.”
They can role a few billion into PLTT now
Very nice Steve...should see a PR at some point. Those are some serious heavy hitters
No kidding, PR might be coming then... That would be real nice to see tomorrow!
This could run so fast it would be sick... Grabbed another 2500...
I checked the website yesterday, that update wasn't there.
This is another SOYO type hold for me, very few I wait out, this one is tops.
Somebody was smart enough to check the website... It's a shame it took you so long Steve, Come on! hehe!
I added that 5K, Excellent Find!
I added to my position another 10K shares .23, now we know why someone was sneaking on those shares.
their website is updated.
Holy Chit where did that come from, you think they might have PR'd it...
Read this press release lol:
http://www.pilottherapeutics.com/11.html
October 19, 2007
Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
WINSTON-SALEM, N.C.- Pilot Therapeutics Inc., a Nutritional Therapeutics Innovation Company, today announced the appointment of Ross Consaul as CEO and Keith Wakeman as President.
“Pilot has always had promising technology and patents in the food, medical food and dietary supplement areas with over 60 issued and pending patents. These new additions will unlock the potential to rapidly move our world class technologies and IP to the marketplace,” said Dr. Floyd “Ski” Chilton, Founder and Chief Technology Officer of Pilot Therapeutics Inc.
Ross joins Pilot with over 20 years experience leading New Ventures, R&D, and New Product Development for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi. He was most recently Nutrition General Manager for Bayer BioScience where he was responsible for identifying and creating new health and nutrition businesses for Bayer.
Keith brings over 20 years of management experience in the food and nutrition industry leading Marketing, Innovation and New Ventures organizations for major companies including Kellogg, Keebler and Nabisco. He was most recently President of Cherry Street Innovation LLC, an innovation company he founded to identify and develop new growth platforms through new ventures and brand innovation.
Former President Scott Derks will remain with Pilot as Vice President, Operations.
“Collectively, Ross and Keith have created new businesses generating nearly $3 billion revenue and bring tremendous experience in health and nutrition. We are delighted to welcome them to our team,” said Chilton.
###
Pilot Therapeutics is a Nutritional Therapeutics Innovation Company dedicated to the prevention and treatment of chronic inflammatory diseases. Through its Functional LiponomicsTM discovery platform, Pilot examines the influence of fatty acids on the expression of genes that control the inflammatory and allergic process. Utilizing this technology Pilot has developed a pipeline of medical foods for the prevention and treatment of numerous chronic inflammatory disorders in humans and animals. These innovative products are based on over 60 issued and pending domestic and international patents.
Pilot Therapeutics was founded by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine. Chilton is also director of the Wake Forest and Brigham and Women’s Program for Botanical Lipids which is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.
.19 X .23 5k knocked out .21, thin as always...
Yep, somebody had been waiting a while to grab those too...
Somebody must want some... maybe the start of something...
.19 x .21 bid ut moments ago.
Thanks,
Mike
Does sound really interesting..
This is as cheap as it has been since it woke back up...
I may follow
Chris here is the Update from the company last year on the website...
LETTER TO STOCKHOLDERS PILOT THERAPEUTICS INC.
November 8, 2006
Dear Stockholder:
If your first reaction to a stockholder’s letter from Pilot Therapeutics Holdings, Inc. ( “Pilot”) is surprise, that is understandable. For the past three years, Pilot has largely been in hibernation. As you will recall Pilot is a medical foods company, based first in Winston-Salem, NC and later in Charleston, SC, which developed an over-the-counter treatment for asthma.
Pilot’s last formal communication with you was in the summer of 2003, when the company had conducted several clinical trials and was launching a promising market test for an over-the-counter asthma product, known as Airozin. But when funding promises failed, the company was forced to close its doors. Since then several attempts have been made to get this clinically-tested product into the marketplace in the dietary supplementand medical foods areas by partnering with other companies. These efforts were largely unsuccessful until interest in Pilot’s intellectual property was ignited by the publication of the two books, Inflammation Nation (Simon and Schuster, 2005) and Win the War Within (Rodale, 2006) by Pilot founder Floyd “Ski” Chilton. The book examined the impact that our modern diet and in particular fatty acids are having on inflammatory diseases as diverse as allergy, arthritis, asthma and eczema.
The purpose of this letter is to inform you that Pilot and Wake Forest University Health Sciences have separately licensed their respective rights of Airozin to Efficas, Inc. of Boulder, Colorado, which is marketing three products based on this technology -- Efficas: Asthma Care; Efficas: Allergy Care; and Efficas: Eczema Care. To view the products link to www.Efficas.com. A press release announcing this transaction from Wake Forest University Health Sciences is attached.
This transaction has provided Pilot the ability to reconstitute its board of directors and begin the process of sorting out the legal, accounting and regulatory issues that naturally arise for a company that goes through essentially three years of dormancy. Pilot is also examining its remaining intellectual property related to other medical food and prescription products--some of which is owned jointly with Wake Forest Medical University Health Sciences --to determine which products should be developed actively by Pilot and which products should be licensed to potential partners.
Pilot has reestablished an office in Winston-Salem at 635 West Fourth Street, Suite 200, 27101. The board is in the process of determining the best structure for the company going forward. Current Board members are Mike Sandusky, President, Business Carolina, Inc; John Ciannamea, Academy Funds; Floyd “Ski” Chilton, founder, professor of physiology and pharmacology at Wake Forest University School of Medicine; and Scott Derks, President of Pilot.
At this time, we are unable to predict the future, but remain hopeful about the potential of products and the quality of the intellectual property owned by Pilot. Please feel free to contact me at the above address or sderks@kimbanet.com to express your thoughts.
Please note that any statements made in this letter related to future prospects for Pilot are forward looking and are made pursuant to the safe harbor established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management’s beliefs and assumptions and involve risks and uncertainties which may cause results to differ materially from the results predicted. These forward-looking statements are identified by terms and phrases such as “hopeful”, “anticipate”, “believe”, “intend”, “expect”, “continue”, “should”, “could”, “may”, “plan”, “project”, “predict”, “will”, and similar expressions. Factors that could cause actual results to differ materially from those indicated in any forward-looking statement include, but are not limited to, unanticipated changes in costs; political, legal, and economic conditions and developments; changing market conditions and other factors; availability of, or cost of, capital; delays and other obstacles associated with investments in joint ventures; and costs and effects of legal and administrative proceedings, settlements, investigations, and claims. Please refer to the company′s SEC filings for additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to update the information contained herein.
Thank you for your patience.
Sincerely,
Pilot Therapeutics Holdings, Inc.
Ss/ Scott Derks
President
Thanks, I added a few...
Website back online, http://www.pilottherapeutics.com/
I was wondering about that when I was going through the info on the stock. Thanks for the update.
Website will be back up, billing ran the payment against an expired credit card.
got my interest going. SSP you dont have many LT plays.. This and SOYO come to mind. Looks like something special.
Yes thank you, it's more settling to know it wasn't an insider or the like.
Thanks for your honesty it is appreciated.
Mike
Had to let mine go today. Wanted to get more into another stock I've been watching, FMNLF. I e-mailed Floyd Chilton over the weekend hoping for a status update and got no response. I'll continue to keep PLTT on my radar.
Some selling off today, anyone from here? I noticed a few days ago the website was down, wondering if someone here noticed that and decided to sell their shares.
March 4, 2007
Colorado Company To Sell Medical Food Products Based On Wake Forest Discovery
A Colorado-based company is launching a line of "medical- food" products for the dietary management of asthma, eczema and other allergic conditions based on discoveries by Floyd H. "Ski" Chilton, Ph.D., of Wake Forest University Health Sciences (WFUHS).
Chilton's discoveries originally led to the founding of a company called Pilot Therapeutics. Now Pilot Therapeutics and WFUHS have licensed rights to the technology to Efficas Inc. of Boulder, Colo., to allow Efficas to produce and market the therapeutic products, said Michael A. Batalia, Ph.D., director of the Office of Technology Asset Management at Wake Forest.
The EfficasTM Care products are aimed at three health conditions: asthma, eczema and allergy. The Efficas Care line is now available for online purchase.
Research by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine, focuses on the role that diet or medical foods play in human disease. As the founder of Pilot Therapeutics, he developed an over-the-counter medical food designed to reduce the production of leukotrienes, substances known to play a significant role in asthma and allergy attacks.
"Through our research and clinical trials, we have learned that allergic individuals have a unique dietary need for two fatty acids, GLA (gamma-linolenic acid) and EPA (eicosapentaenoic acid)," Chilton said. "Our studies also show that increased consumption of these nutrients can inhibit leukotriene production in patients."
The new products contain a patented formula of marine oil and botanical oil (borage seed oil) that contains the optimal amount and ratio of GLA and EPA.
"The new licensing arrangement between Efficas, WFUHS and Pilot Therapeutics will allow both companies to advance new technology," Batalia said. "Efficas is a well-funded health science and technology development company with the resources to market these new products, and Pilot Therapeutics now can move on to other product developments."
Besides founding Pilot Therapeutics, Chilton is also director of a WFUHS research program studying dietary supplements, one of five in the country. The program is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.
The Wake Forest program is a partnership with Brigham and Women's Hospital in Boston and is known as the Wake Forest and Brigham and Women's Program for Botanical Lipids. Botanicals are plant-based dietary ingredients. One of the four main research projects focuses on how borage, marine and echium oils reduce inflammatory messengers that cause diseases such as asthma and arthritis. (Echium oil is a natural vegetable oil rich in short-chain omega-3 polyunsaturated fatty acids that are converted by humans to the fat equivalent of fish oil.)
Efficas, Inc. is a Boulder-based health science and technology development company "committed to developing science-based products for the nutritional management of the immune system both for humans and pets," according to a company news release.
Efficas has received funding from Life Science Partners BioVentures, Burrill and Company, Great Spirit Ventures, Unilever Technology Ventures, JP Morgan Bay Area Equity Fund and Prolog Ventures
"Immune-related conditions affect millions of people and we believe leukotriene-inhibiting technology holds great promise for improved quality of life for these individuals," said Mark Braman, chief executive officer of Efficas.
"Marketing first via the Web allows us to efficiently reach out to the millions of proactive consumers who are seeking information and alternative treatments online," Braman said. "We will follow with specialty and natural retail distribution, then mass retail distribution to make our products more easily accessible to the broader population."
###
Wake Forest University Baptist Medical Center is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university's School of Medicine and its other related enterprises including the Piedmont Triad Research Park. The Medical School is ranked 4th in the Southeastern United States in revenues from its licensed intellectual property.
Contact: Robert Conn
Wake Forest University Baptist Medical Center
http://allergy-articles.blogspot.com/2007/03/colorado-company-to-sell-medical-food.html
Good article, thanks for sharing that. I still haven't made up my mind on this one, but will continue pondering. I wonder how much cash flow they have?
new article out about PLTT
http://carolinanewswire.com/news/News.cgi?database=1news.db&command=viewone&id=3512&op=t
Pilot Therapeutics subject of feature in April's Business North Carolina
03-27-2007
CHARLOTTE - Nine years ago, Wake Forest University biochemist Floyd “Ski” Chilton — inspired by his ailing younger sister -- got an idea to start a company that would use fatty acids to make food that could treat inflammations such as arthritis, asthma and eczema. Pilot Therapeutics set out to make an edible gel that would use those fatty acids as a medical treatment. Long before it had a product to sell, the company won the attention of investors, then launched a bidding war between the Carolinas before burning through more than $18 million and, presumably, dying in late 2003. But Pilot wasn’t dead, just in a deep coma, according to Business North Carolina magazine. As it turned out, Pilot and its founder, who limped back to Wake Forest to resume a research career, survived encounters with politics and tragedy to re-emerge late last year to sign a deal with a Boulder, Colo.-based company that would make and market its medical foods. Pilot now has its first operating cash flow, and Chilton is cautiously trying to reconstitute the company. Whether it will have better luck this time is another question. Investors are likely to be more discerning, and even biotech-hungry state recruiters are more savvy about their spending.
Chilton plans to do things differently as well. He’s leaving the company’s day-to-day operations to a professional manager, though he will continue to be its chief science officer. Looking back on its disastrous first run, he says, “I was simply an entrepreneur trying to survive.”
Business North Carolina is a Charlotte-based statewide monthly magazine that focuses on the people, events and trends that shape business in North Carolina. Since it began publication in 1981, it has won more than 75 national awards for its writing, reporting and design. www.businessnc.com
For more information: David Kinney, Business North Carolina, 704-523-6987, Ext. 223
One of these days...
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
724
|
Created
|
11/14/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |